CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The aim of this exploratory study is to assess the performance and tolerability of the MOBIDERM Intimate Bra in the management of breast ede ...
Paris, Paris 14, France
adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast...
Phase 2
Saint-Cloud, France and 72 other locations
non-metastatic early-stage triple-negative (TNBC) or HER2+ breast cancer. TNBC cohort is composed of 2 open-label, randomized arms,...
Phase 2
Villejuif, France
Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherap...
Phase 3
Villejuif, France
This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...
Phase 3
Paris Cedex 05, Paris, France and 226 other locations
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...
Phase 1, Phase 2
Villejuif Cedex, France and 71 other locations
-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.During this study, anti-h...
Phase 3
Villejuif, France and 52 other locations
This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abn...
Phase 2
Villejuif, Cedex, France and 36 other locations
participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast...
Phase 1, Phase 2
Paris, France and 26 other locations
This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have...
Phase 2
Villejuif, France
Clinical trials
Research sites
Resources
Legal